Accuray Incorporated
NasdaqGS:ARAY Voorraadrapport
Marktkapitalisatie: US$216.2m
Accuray Dividenden en inkoop
Dividend criteriumcontroles 0/6 Accuray heeft geen dividenduitkeringen gedaan.
Belangrijke informatie Totaal aandeelhoudersrendement -1.0% Toekomstig dividendrendement n/a Dividendgroei n/a Volgende betaaldatum dividend n/a Ex-dividenddatum n/a Dividend per aandeel n/a Uitbetalingsratio n/a
Recente updates van dividend en inkoop
Toon alle updates Accuray Incorporated Raises Financial Guidance for the Fiscal Year Ending June 30, 2025 Nov 07
Accuray Incorporated to Report Q1, 2025 Results on Nov 06, 2024 Oct 24
Accuray Incorporated Announces CEO Changes Oct 15
Accuray Incorporated, Annual General Meeting, Nov 21, 2024 Oct 07 Accuray Incorporated announced delayed annual 10-K filing Sep 17
Accuray Incorporated President Suzanne Winter to Take Temporary Medical Leave of Absence
Accuray Remains A Perpetual 'Next Year Is Our Year' Story Aug 18
Forecast breakeven date pushed back to 2026 Aug 16
New major risk - Share price stability Aug 15
Full year 2024 earnings: EPS and revenues exceed analyst expectations Aug 15
Accuray Incorporated Provides Earnings Guidance for the Fiscal Year 2025 Aug 15
Accuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues Aug 13
Accuray Incorporated to Report Q4, 2024 Results on Aug 14, 2024 Aug 01
Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration Jun 15
Forecast breakeven date pushed back to 2026 Jun 06
Independent Chairman of the Board recently bought US$156k worth of stock Jun 02
Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop May 21
Accuray Incorporated Announces Executive Changes, Effective May 17, 2024 May 11
Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results May 04
Price target decreased by 11% to US$7.75 May 03
Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%? May 03
Accuray Incorporated Provides Earnings Guidance for the Year 2024 May 03
Third quarter 2024 earnings: EPS and revenues miss analyst expectations May 02
Now 35% undervalued after recent price drop May 02
Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024 Apr 26
Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024 Apr 19
Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp Apr 07
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System Mar 26
New minor risk - Shareholder dilution Feb 08
Is Accuray (NASDAQ:ARAY) A Risky Investment? Feb 03
Second quarter 2024 earnings: EPS misses analyst expectations Feb 02 Feb 01
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024 Feb 01
Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024 Jan 17
President recently sold US$162k worth of stock Dec 06
First quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 09
President recently sold US$99k worth of stock Nov 06
Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023 Oct 27
Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration Oct 05
Accuray Incorporated, Annual General Meeting, Nov 09, 2023 Sep 30
Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge Aug 17
Full year 2023 earnings: EPS misses analyst expectations Aug 10
Forecast breakeven date pushed back to 2025 Aug 10 Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024
Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023 Jul 28
President recently sold US$65k worth of stock Jul 06
Insider recently sold US$93k worth of stock Jun 04
Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology May 18
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Apr 28
These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively Apr 13
The Return Trends At Accuray (NASDAQ:ARAY) Look Promising Mar 14
Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A Feb 17
High number of new directors Feb 07
Accuray Incorporated Reiterates Earnings Guidance for the Year 2023 Feb 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 03
Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors Feb 02
Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023 Jan 19
Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System Jan 18
Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023 Dec 23
Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt Dec 01
First quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 05
President recently sold US$76k worth of stock Nov 04
Accuray Incorporated Re-Affirms Guidance for Year 2023 Nov 03
Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration Nov 02
High number of new directors Oct 31
Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price Oct 27
Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia Oct 27
Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022 Oct 20
Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators Oct 12 Accuray Incorporated, Annual General Meeting, Nov 10, 2022
Accuray launches CyberKnife platform in Africa for cancer patients Sep 30
Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated Sep 22
Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer Sep 15
Full year 2022 earnings: EPS and revenues exceed analyst expectations Aug 11
Accuray Incorporated Provides Revenue Guidance for Year 2023 Aug 11
Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M Aug 10
Accuray Incorporated to Report Q4, 2022 Results on Aug 10, 2022 Jul 28
Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications Jul 13
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden Jul 08
Accuray Incorporated(NasdaqGS:ARAY) dropped from Russell 3000E Index Jun 26
Accuray Incorporated Appoints Franco N. Palomba as Chief Accounting Officer & Controller Jun 16
Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger Jun 15
High number of new directors Jun 01
Accuray: Nothing Special May 31
Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer May 18
Accuray Incorporated Announces That Clinical Studies Continue to Validate the Versatility of the Company's Cyberknife® and Tomotherapy® Platforms May 12
High number of new directors May 06
Third quarter 2022 earnings: EPS exceeds analyst expectations Apr 28 Accuray Incorporated Re-Affirms Earnings Guidance for the Fiscal Year 2022
Price target increased to US$8.30 Apr 27
Accuray Incorporated to Report Q3, 2022 Results on Apr 27, 2022 Apr 14
Stabiliteit en groei van betalingen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van ARAY in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van ARAY zijn gestegen.
Dividendrendement versus markt Accuray Dividendrendement versus markt
Hoe verhoudt ARAY dividendrendement zich tot de markt? Segment Dividendrendement Bedrijf (ARAY) n/a Markt onderkant 25% (US) 1.3% Markt Top 25% (US) 4.3% Gemiddelde industrie (Medical Equipment) 1.7% Analist prognose (ARAY) (tot 3 jaar) n/a
Opmerkelijk dividend: Het dividendrendement van ARAY kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van ARAY kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio ARAY te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat ARAY geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
